Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
About Index
Index
By TNW
Log in
Register
Aerie Pharmaceuticals
3199
Aerie Pharmaceuticals
Technology
Biotechnology
Health Care
Medical
Pharmaceuticals
Aerie Pharmaceuticals is focused on developing products for the pharmaceuticaltreatment of glaucoma.
Suggest edits
Type
B2c
Founded
2005
Raised
$331.4M
Follow us
Companies in the same industry
Atriva Therapeutics
ViraCyte
Glionova Therapeutics
Zensun (Shanghai) Sci & Tech Co.
DoveTail Integrated Systems
Selvita
Apexigen
Napajen Pharma
CinCor Pharma
Metis Precision Medicine
Alexa global traffic share
Overview
Funding
4
Add info
Latest funding
Show all
$40,000,000
Undisclosed - 2017
Novartis Venture Fund
Venture Investors
OrbiMed
+3
$125,000,000
Post-IPO equity - 2016
Team Size
10+
Employees
I work here
Location
United States
Headquarters
Explore United States
Pulse 2.0
Aerie Pharmaceuticals (AERI) Stock: Why It Substantially Increased
Pulse 2.0
Aerie Pharmaceuticals Stock (AERI): Why The Price Fell Today
$40,000,000
Undisclosed
PE HUB
Aerio Pharmaceuticals takes in about $40 mln
Funding
Messaging
$125,000,000
Post-IPO equity
businesswire
Aerie Pharmaceuticals Raises $125 Million in Public Offerings | Business Wire
The Motley Fool
Why Safety Data Is Sending Aerie Pharmaceuticals Soaring Today
Stock markets